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84 Letters to the Editorof SIADH by lopinavir was probably responsible for the severe
hyponatraemia in our patient.
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doi:10.1016/j.ijid.2005.11.002Figure 1 Overall antimicrobial drug susceptibility (%) of Pseu-
domonas aeruginosa isolated from pediatric infections against
tested antibiotics (WGH, Venezuela, 1997—2003).Antimicrobial resistance of Pseudomonas aeru-
ginosa in pediatric infections
Problems encountered in the management of pediatric infec-
tions include treatment failure, which often occurs as a result
of antimicrobial-resistant bacterial strains; especially among
Pseudomonas aeruginosa.1,2 For this reason antimicrobial
drug activity surveillance is necessary, especially for oppor-
tunistic and nosocomial P. aeruginosa.2
In Latin America, resistant bacteria are emerging as a real
threat in the community as well as in hospital-acquired
infections, including pediatric infections.2 We reviewed sus-
ceptibility data of isolates cultured from hospitalized pedia-
tric patients with suspected community-acquired infections
in the West General Hospital (WGH) Caracas, Venezuela
between 1997 and 2003. The WGH is a 300-bed general
community hospital serving people from west Caracas. Sam-
ples were taken before antimicrobial drug therapy was com-
menced. Samples were processed and organisms identified by
traditional methods. In vitro antimicrobial susceptibility of
the isolates was assessed by an agar disk diffusion method
using Mueller—Hinton agar as recommended by the Clinical
and Laboratory Standards Institute (formerly NCCLS). Anti-
pseudomonal third generation cephalosporins and carbape-
nems are freely prescribed in hospitalized patients but
previous antimicrobial drug exposure in this patient series
was not measured; there were no chronic conditions
reported.
During this seven-year period, P. aeruginosa accounted
for 137 (4%) of 3425 bacterial isolates from children: 49%
from otorrhinolaryngological (ORL) infections, 18% urinary
tract infections, 7% skin, and 7% gastrointestinal tract,
among others. Overall susceptibility rates are shown in
Figure 1. Better antimicrobial activity was observed withciprofloxacin, meropenem, and imipenem (<5% resistant)
than for gentamycin, piperacillin and piperacillin/tazobac-
tam (>10% resistant). For urinary isolates, we found strains
resistant to norfloxacin (13%) and gentamycin (8%), but only
intermediate resistance to aztreonam, ceftazidime, and
ciprofloxacin (8% for each). Susceptibility to imipenem,
piperacillin/tazobactam, and tobramycin was 100%. In ORL
infections, we found significant resistance to carbenicillin
(18%) and some resistance to meropenem (5%) and imipenem
(3%) but 100% susceptibility to ciprofloxacin, ofloxacin, and
piperacillin/tazobactam.
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reported in nosocomial P. aeruginosa, community-acquired
data are less frequently reported. For this reason, epidemio-
logical studies on the prevalence and antimicrobial suscept-
ibility patterns of resistant isolates in different geographical
settings, would provide useful information for both empirical
treatment of suspected infections and better management of
patients.
Our results show that in our setting imipenem is still very
active against strains of P. aeruginosa in pediatric infections,
although other studies have reported higher resistance
rates.3,4 Recent studies have reduced safety concerns over
the use of quinolones in pediatric patients. Combined with
the good antimicrobial activity shown in this and other
studies,5 this makes them a good empirical choice for
community-acquired infections. Local surveillance of
antimicrobial activity should be done periodically to guide
antimicrobial therapy, especially as carbapenem-resistant
P. aeruginosa has been reported as an emerging problem in
Latin America.6
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doi:10.1016/j.ijid.2005.10.010Unrecognized near-fatal hyperlactatemia in
an HIV-infected infant exposed to nucleoside
reverse transcriptase inhibitors
Nucleoside analogue reverse transcriptase inhibitors (NRTIs)
inhibit mitochondrial DNA (mtDNA) polymerase gamma
thereby interfering with mtDNA replication.1—3 The relative
potency of the NRTIs in causing mitochondrial dysfunction is
highest for zalcitabine, followed by didanosine, stavudine,
and zidovudine. Lamivudine, abacavir, and tenofovir have
lower affinity for mtDNA polymerase.4 In utero and perinatal
exposure to NRTIs are known to cause hyperlactatemia (HLA)
from mitochondrial toxicity.5,6
An HIV-infected mother detected at 30 weeks of preg-
nancy was treated with lamivudine, stavudine, and nevira-
pine. A live male baby weighing 2135 g was delivered by
elective cesarean section at 38 weeks of gestation with
intrapartum intravenous zidovudine cover as per PACTG076 protocol.7 He was discharged well with oral zidovudine
on the third day.
At three weeks old he developed fever, abdominal dis-
tension, diarrhea, and vomiting, which required treatment
with intravenous fluids and antibiotics, and was discharged
well after 12 days. At five weeks old he returned with
diarrhea, poor feeding, dehydration, and acidotic breathing.
Arterial blood pH was 7.13, pO2 128 mmHg, pCO2 18.7 mmHg,
base excess 21.9 mmol/L, and anion gap 24 mmol/L.
Serum lactate and ammonia levels were 4.07 mmol/L and
203.6 mmol/L, respectively. Serum aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), and gamma glu-
tamyltransferase (GGT) levels were 89, 189, and 166 IU/L,
respectively. Serum albumin was 28 g/L with prolonged acti-
vated partial thromboplastin time (APTT) and increased
prothrombin time (PT) ratio. Repeated hemoculture and
stool cultures did not yield any pathogen. His urine was
screened for inborn errors of metabolism but proved normal.
On the second hospital day he developed jerking movements
